Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

TitleBevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Publication TypeJournal Article
Year of Publication2015
AuthorsPoveda, AM, Selle, F, Hilpert, F, Reuss, A, Savarese, A, Vergote, IB, Witteveen, P, Bamias, A, Scotto, N, Mitchell, L, Pujade-Lauraine, E
JournalJ Clin Oncol
Volume33
Issue32
Start Page3836
Pagination3838
Date Published11/2015
ISSN1527-7755
KeywordsAdult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Doxorubicin, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Platinum Compounds, Polyethylene Glycols, Prognosis, Risk Factors, Topotecan, Treatment Outcome
DOI10.1200/JCO.2015.63.1408
Alternate JournalJ. Clin. Oncol.
PubMed ID26282651